HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Hwang, D.-R. Articles by Welch, M. J. Search for Related Content PubMed PubMed Citation Articles by Hwang, D.-R. Articles by Welch, M. J.

N-3-[¹⁸F]Fluoropropylputrescine as Potential PET Imaging Agent for Prostate and Prostate Derived Tumors

Edward Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, Missouri
Department of Urology, Baylor College of Medicine, Houston, Texas

Correspondence: For reprints contact: M. J. Welch, PhD, Edward Mallinckrodt Institute of Radiology, Washington University School of Medicine, 510 So. Kingshighway Blvd., St. Louis, MO 63110.

ABSTRACT

A potential PET imaging agent for prostate and prostate derived tumors, N-3-[¹⁸F]-fluoropropylputrescine, has been prepared. The radiochemical yield was 7–10% at end-of-synthesis (EOS) and the specific activity was >1.1 Ci/µmol (overall synthesis time was 1.5 hr). In vivo biodistribution in mature male rats showed high prostate uptake. In rats that were pretreated with -difluoromethylomithine and dihydrotestosterone propionate, the prostate to muscle ratio and prostate to blood ratio increased significantly. This high target uptake and target to nontarget ratio indicates the potential of this compound as a prostate imaging agent.